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INTRODUCTION 
Snake bite is an occupational disease of farmers, plantation 
workers, herdsmen, fishermen, snake workers and other food 
producers. It is therefore a medical problem that has important 
implications for the nutrition and economy of the countries where it 
occurs commonly. 
Despite its importance, there have been fewer proper clinical 
studies of snake bite than of almost any other tropical disease. 
Snakebites probably cause more deaths in the region than do 
Entamoeba histolytica infections but only a small fraction of the 
research investment in amoebiasis has been devoted to the study of 
snake-bite.It would be better if  governments, academic institutions, 
pharmaceutical, agricultural and other industries and other funding 
bodies,actively encourage and sponsor properly designed clinical 
studies of all aspects of snake-bite. 
Snake Bites is a major health problem in India. India alone 
contributes to about 81,000 envenomations and 11,000 deaths 
annually. In Tamilnadu envenomations occur commonly due to 
snakes of Elapidae and Viperidae families causing local and 
systemic manifestations. 
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Cardiotoxicity has been recognized as a feature of snake 
envenoming. However, it is the neuromuscular paralysis and the 
respiratory failure with elapid bites and the coagulation 
abnormalities in viperine bites, which dominate treatment efforts in 
patients. 
Cardiac involvement has not been fully studied earlier and so 
the present study is undertaken. This study is likely to contribute to 
the importance of assessing the cardiac status in snake 
envenomation. 
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AIMS AND OBJECTIVES 
SIGNIFICANCE OF RESEARCH 
To bring out the cardiac involvement in snake envenomation 
and to provide additional insights for management. 
RESEARCH QUESTIONS 
1) How many persons with snake bite have cardiac involvement? 
2) What are the patterns of cardiac involvement? 
3) Whether cardiac involvement has any clinical significance? 
4) Do the patients with cardiac involvement need any special care. 
OBJECTIVES 
1) To find out the pattern of cardiac involvement in Snake 
Envenomation. 
2) To elicit the Electrocardiographic abnormalities and 
functional status of heart during snake envenomation.  
3) To analyse the variations in cardiac involvement with 
reference to different species of snakes. 
4) To identify the importance of biomarkers in recognizing 
cardiac involvement. 
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REVIEW OF LITERATURE1 
There are more than 3000 species of snakes in the world. For 
the purpose of clinical practice, snakes are classified into poisonous 
(venomous) and non-poisonous (non venomous) snakes. Poisonous 
snakes are classified into three families and they are 
 Cobra group [Elapidae] 
 Viper group [Viperidae] 
 Sea snake group [Hydrophidae] 
For many decades, the concept of the “Big 4” snakes of 
medical importance has reflected the view that 4 species 
responsible for Indian snakebite mortality. They are - Indian cobra 
(Naja naja),Common Krait (Bungarus caeruleus),Russell’s viper 
(Daboia russelii) and  Saw scaled viper (Echis carinatus).However, 
recently another species, the Hump-nosed pit viper (Hypnale 
hypnale), has been found to be capable of causing lethal 
envenomation, and this problem has not been recognised because of 
systematic misidentification of this species as the saw-scaled viper.  
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CIRCUMSTANCES OF SNAKE-BITES 
Most snake bites happen when the snake is trodden on, either 
in the dark or in undergrowth, by someone who is bare footed or 
wearing only sandals. The snake may be picked up, unintentionally 
in a handful of foliage or intentionally by someone who is trying to 
show off. Some bites occur when the snake (usually a krait) comes 
into the home at night in search of its prey (other snakes, lizards, 
frogs, mice) and someone sleeping on the floor rolls over onto the 
snake in their sleep.2  
EPIDEMIOLOGY 
India: The numbers of snake-bite fatalities in India has long 
been controversial. Estimates as low as 61,507 bites and 1,124 
deaths in 2006 and 76,948 bites and 1,359 deaths in 2007 and as 
high as 50 000 deaths each year have been published.3 Previous 
studies including  a field survey in randomly selected villages in 
Barddhaman (Burdwan) district, West Bengal suggested that among 
the total population of nearly five million people, nearly 8 000 were 
bitten and 800 killed by snakes each year, an average incidence of 
16.4 deaths/100 000/year. In Maharashtra State, between 1974-78, 
there were an average of 1224 deaths/year (2.43 deaths/100 
000/year). “The big four” medically important species had been 
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considered to be Naja naja, Bungarus caeruleus, Daboia russelii 
and Echis carinatus but other species have now been proved 
important in particular areas, such as Naja oxiana(north-west), N. 
kaouthia (north-east), Hypnale hypnale (south-west coast and 
Western Ghats (Joseph et al., 2007)), Echis 
carinatussochureki(Rajasthan) (Kochar et al., 2007) and 
Trimeresurus malabaricus(Hassan district, Mysore, Karnataka). 
VENOM COMPOSITION 
More than 90% of snake venom (dry weight) is protein.Snake 
venom contains more than a hundred different proteins;enzymes 
(constituting 80-90% of viperid and 25-70% of elapid venoms), 
non-enzymatic polypeptide toxins, and non-toxic proteins such as 
nerve growth factor. 
VENOM ENZYMES4,5,6 
These include digestive hydrolases, hyaluronidase and 
activators or inactivators of physiological processes, such as 
kininogenase. Most venoms contain l-amino acid oxidase, 
phosphomono- and diesterases, 5’-nucleotidase, DNAase, NAD-
nucleosidase, phospholipase A2 and peptidases. 
Zinc metalloproteinase haemorrhagins: Damage vascular 
endothelium, causing bleeding. 
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Procoagulant enzymes: Venoms of Viperidae and some 
Elapidae and Colubridae contain serine proteases and other 
procoagulant enzymes that are thrombin-like or activate factor X, 
prothrombin and other clotting factors. 
These enzymes stimulate blood clotting with formation of 
fibrin in the bloodstream. Paradoxically, this process results in 
incoagulable blood because most of the fibrin clot is broken down 
immediately by the body’s own plasmin fibrinolytic system and, 
sometimes within 30 minutes of the bite, the levels of clotting 
factors are so depleted (“consumption coagulopathy”) that the 
blood will not clot. Some venoms contain multiple anti-haemostatic 
factors. 
Phospholipase A2 (lecithinase): The most widespread and 
extensively studied of all venom enzymes. It damages 
mitochondria, red blood cells,leucocytes, platelets, peripheral nerve 
endings, skeletal muscle, vascular endothelium, and other 
membranes, produces presynaptic neurotoxic activity,opiate-like 
sedative effects, leads to the autopharmacological release of 
histamine and anti-coagulation. 
Acetylcholinesterase: Although found in most elapid 
venoms, it does not contribute to their neurotoxicity. 
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Hyaluronidase: Promotes the spread of venom through 
tissues. 
Proteolytic enzymes (metalloproteinases, endopeptidases or 
hydrolases) and polypeptide cytotoxins (“cardiotoxins”): Increase 
vascular permeability causing oedema, blistering, bruising and 
necrosis at the site of the bite. 
VENOM POLYPEPTIDE TOXINS (“NEUROTOXINS”)  
Postsynaptic (α) neurotoxins such as α-bungarotoxin and 
cobrotoxin, consist of 60-62 or 66-74 amino acids.They bind to 
acetylcholine receptors at the motor endplate. Presynaptic (β) 
neurotoxins such as β-bungarotoxin, crotoxin,and taipoxin, contain 
120-140 amino acids and a phospholipase A subunit. 
These release acetylcholine at the nerve endings at 
neuromuscular junctions and then damage the endings, preventing 
further release of transmitter. 
CONSEQUENCES OF SNAKE-BITE 
Victims of snake-bite may suffer any or all of the following: 
1) Local envenoming confined to the part of the body that has 
been bitten. These effects may be debilitating, sometimes 
permanently. 
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2) Systemic envenoming involving organs and tissues away from 
the part of the body that has been bitten. These effects may be 
life threatening and debilitating, sometimes permanently. 
3) Effects of anxiety prompted by the frightening experience of 
being bitten and by exaggerated beliefs about the potency and 
speed of action of snake venoms. These symptoms can be 
misleading for medical personnel. 
4) Effects of first-aid and other pre-hospital treatments that may 
cause misleading clinical features. These may be debilitating 
and rarely even life-threatening. 
Last two symptoms may develop in patients who are 
envenomed and in those who are not envenomed (bite by a non-
venomous snake or by a venomous snake that failed to inject 
venom) or who were not in fact bitten by a snake at all but by a 
rodent or lizard or even impaled by a thorn. 
SYMPTOMS AND SIGNS OF SNAKE-BITE 
When venom has not been injected 
Anxious people may hyperventilate so that they develop pins 
and needles sensation of the extremities, stiffness or tetany of their 
hands and feet and dizziness. Others may develop vasovagal shock 
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after the bite or suspected bite-faintness and collapse with profound 
slowing of the heart. Others may become highly agitated and 
irrational and may develop a wide range of misleading symptoms. 
Blood pressure and pulse rate may increase and there may be 
sweating and trembling. Another source of symptoms and signs not 
caused by snake venom is first aid and traditional treatments.7 
Constricting bands or tourniquets may cause pain, swelling and 
congestion that suggest local envenoming. Ingested herbal remedies 
may cause vomiting. 
When venom has been injected 
Early symptoms and signs 
Following the immediate pain of mechanical penetration of 
the skin by the snake’s fangs, there may be increasing local pain at 
the site of the bite, local swelling that gradually extends proximally 
up the bitten limb and painful enlargement of the regional lymph 
nodes draining the site of the bite.However, bites by kraits may be 
virtually painless and may cause negligible local swelling.If the 
biting species is unknown, the patient should be observed closely to 
allow recognition of the emerging pattern of symptoms, signs and 
laboratory results(“the clinical syndrome”), together with other  
evidence, that may suggest which species was responsible. 
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Local symptoms and signs in the bitten part 
1) fang marks  
2) local pain 
3) local bleeding  
4) bruising,blistering  
5) lymphangitis (raised red lines tracking up the bitten 
limb) 
6) regional lymph node enlargement 
7) inflammation (swelling, redness,warmth) 
8) local infection, abscess formation necrosis  
General 
Nausea, vomiting, malaise, abdominal pain, weakness, 
drowsiness, prostration. 
CARDIOVASCULAR  MANIFESTATIONS(ELAPIDAE AND 
VIPERIDAE) 
General symptoms of visual disturbances, dizziness, 
faintness, collapse, shock.Autonomic disturbances in the form of 
hypotension,hypertension,bradycardia,tachycardia,cardiac 
arrhythmias in the form of conduction blocks and ventricular 
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tachyarrythmias,myocardial involvement resulting in 
myocarditis,cardiomyopathy and acute pulmonary oedema. 
Nayak et al have documented the range of cardiac 
manifestations in snake bite. The mechanism of cardiac 
involvement in neurotoxic snake bite is not clear.  However it is 
possibly  due to one of the myriad toxins seen in snake venom, 
which can cause morphological changes, enzyme alteration, 
ultrastructural disturbance and genetic alterations of the myocardial 
tissue. 
BLEEDING AND CLOTTING DISORDERS (VIPERIDAE) 
Traumatic bleeding from recent wounds (including prolonged 
bleeding from the fang marks and from old partly-healed wounds). 
Spontaneous systemic bleeding - from gums,epistaxis, 
bleeding into the tears, intracranial haemorrhage (meningism from 
subarachnoid haemorrhage, lateralizing signs and/or coma from 
cerebral haemorrhage), haemoptysis, haematemesis, rectal bleeding 
or melaena, haematuria, vaginal bleeding, ante-partum haemorrhage 
in pregnant women, bleeding into the mucosae , skin (petechiae, 
purpura, discoid haemorrhages and ecchymoses) and retina. 
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Cerebral arterial thrombosis (Russell’s viper Daboia 
russelii) Thrombotic strokes, confirmed by angiography or 
imaging, are reported  rarely  after envenoming by D. russelii.8 
NEUROLOGICAL MANIFESTATIONS (ELAPIDAE, 
RUSSELL’S VIPER) 
Drowsiness, paraesthesiae, abnormalities of taste and smell, 
“heavy” eyelids, ptosis , external ophthalmoplegia, paralysis of 
facial muscles and other muscles innervated by the cranial 
nerves,bulbar paralysis resulting in nasal voice or aphonia,nasal 
regurgitation, difficulty in swallowing secretions, respiratory and 
generalised descending flaccid paralysis can all occur in Elapide 
and Russell’s viper bites. 
RHABDOMYOLYSIS (SEA SNAKES, SOME KRAIT SPECIES  
Bungarus niger and B. candidus, Russell’s viper Daboia russelii) 
Generalized pain, stiffness and tenderness of muscles, 
trismus, myoglobinuria, hyperkalaemia, cardiac arrest, acute renal 
failure result from rhabdomyolysis. 
RENAL  MANIFESTATIONS(VIPERIDAE, SEA SNAKES) 
Renal manifestations result in loin (lower back) pain, 
haematuria, haemoglobinuria, myoglobinuria, oliguria/anuria, 
symptoms and signs of uraemia (acidotic breathing, hiccups, 
nausea, pleuritic chest pain )9 in Viperine and sea snake bites. 
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ENDOCRINE MANIFESTATIONS  
Acute pituitary  and adrenal insufficiency from infarction of 
the anterior pituitary (Russell’s viper in Myanmar and South 
India)10 has also been reported.This may manifest during the  Acute 
phase as shock and hypoglycaemia. 
In the chronic phase (months to years after the bite): 
Weakness, loss of secondary sexual hair, loss of libido, 
amenorrhoea, testicular atrophy and hypothyroidism may occur. 
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SYNDROMIC APPROACH TO SNAKE BITE 
 
Syndrome-1 
 Local envenoming (swelling etc.) with bleeding/clotting 
disturbances - Viperidae (all species). 
 
Syndrome-2 
 Local envenoming (swelling etc.) with bleeding/clotting 
disturbances, shock or acute kidney injury - Russell’s 
viper, Hump-nosed pit viper in Sri Lanka and South India. 
 Conjunctival oedema (chemosis) and acute pituitary 
insufficiency - Russell’s viper. 
 Ptosis, external ophthalmoplegia, facial paralysis etc 
and dark brown urine - Russell’s viper in Sri Lanka and 
South India. 
 
Syndrome-3 
 Local envenoming (swelling etc.) with  neuromuscular 
paralysis - cobra or king cobra. 
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Syndrome-4 
Paralysis with minimal or no local envenoming. 
 Bitten on land while sleeping on the ground – krait. 
 Bitten in the sea, estuary and some freshwater lakes - 
sea snake. 
Syndrome-5 
Paralysis with dark brown urine and acute kidney injury 
 Bitten on land (with bleeding/clotting disturbance) - 
Russell’s viper, Sri Lanka and South India. 
 Bitten on land while sleeping indoors - krait (B. niger, B. 
candidus, B. multicinctus). 
 Bitten in sea, estuary and some freshwater lakes (no 
bleeding/clotting disturbances) - sea snake. 
LIMITATIONS OF SYNDROMIC APPROACH  
The more carefully the clinical effects of snake-bites are 
studied, the more it is realized that the range of activities of a 
particular venom is very wide. For example, some elapid venoms, 
such as those of Asian cobras, can cause severe local envenoming, 
formerly thought to be an effect only of viper venoms. In Sri Lanka 
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and South India, Russell’s viper venom causes paralytic signs 
(ptosis, etc.). Although there may be considerable overlap of 
clinical features caused by venoms of different species of snake, a 
“syndromic approach” may still be useful, especially in resource 
poor settings. 
LONG TERM COMPLICATIONS  OF SNAKE-BITE 
At the site of the bite, loss of tissue may result from 
sloughing or surgical debridement of necrotic areas or 
amputation.Chronic ulceration, infection, osteomyelitis, 
contractures, arthrodesis or arthritis may persist causing severe 
physical disability . Malignant transformation may occur in skin 
ulcers after a number of years. Chronic kidney disease (renal 
failure) occurs after bilateral cortical necrosis (Russell’s viper and 
hump-nosed pit viper bites) and chronic panhypopituitarism or 
diabetes insipidus after  Russell’s viper bites in Myanmar and 
South India.Chronic neurological deficit is seen in the few patients 
who survive intracranial haemorrhages and thrombosis (Viperidae). 
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MANAGEMENT OF SNAKE-BITE 
 
 First aid treatment 
 Transport to hospital 
 Detailed clinical assessment  
 Investigations/laboratory tests 
 Antivenom treatment 
 Observing the response to antivenom 
 Deciding whether further dose(s) of antivenomare needed 
 Treatment of the bitten part 
 Rehabilitation 
 Treatment of chronic complications 
AIMS OF FIRST-AID 
The main aims of first aid treatment are to retard the  
systemic absorption of venom and to preserve life and prevent 
complications before the patient can receive medical care and 
control distressing or dangerous early symptoms of envenoming. 
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The patient should be transported  to a place where they can receive 
medical care. 
RECOMMENDED FIRST-AID METHODS 
Reassure the victim who may be very anxious. 
Immobilize the whole of the patient’s body by laying him/her 
down in a comfortable and safe position and especially, immobilize 
the bitten limb with a splint or sling. Any movement or muscular 
contraction increases absorption of venom into the blood stream 
and lymphatics. 
If the necessary equipment and skills are available, consider 
pressure-immobilization or pressure pad unless an elapid bite can 
be excluded. Avoid any interference with the bite wound (incisions, 
rubbing, vigorous cleaning, massage, application of herbs or 
chemicals) as this may introduce infection, increase absorption of 
the venom and increase local bleeding.11 
            
            The use of tight tourniquets have been traditionally used to stop 
venom flow into the body following snakebite however  there is an 
increased risk of ischemia and local necrosis and  risk of massive 
neurotoxic blockade when tourniquet is released. 
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RELEASE OF TIGHT BANDS, BANDAGES AND 
LIGATURES  
Ideally, these should not be released until the patient is under 
medical care in hospital, resuscitation facilities are available and 
antivenom treatment has been started .12 
DETAILED CLINICAL ASSESSMENT AND SPECIES 
DIAGNOSIS 
History 
A precise history of the circumstances of the bite and the 
progression of local and systemic symptoms and signs is very 
important. 
A common early symptom of systemic envenoming is 
vomiting.Patients who become defibrinogenated or 
thrombocytopenic may begin to bleed from old, partially-healed 
wounds as well as bleeding persistently from the fang marks. The 
patient should be asked how much urine has been passed since the 
bite and whether it was of a normal colour. Patients who complain 
of sleepiness, drooping eyelids or blurred or double vision may 
have neurotoxic envenoming. 
An important early symptom of sea snake envenoming that 
may develop as soon as 30 minutes after the bite is generalized 
pain, tenderness and stiffness of muscles and trismus. 
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EARLY CLUES THAT A PATIENT HAS SEVERE 
ENVENOMING 
 Snake identified as a very dangerous one. 
 Rapid early extension of local swelling from the site of the 
bite. 
 Early tender enlargement of local lymph nodes, indicating 
spread of venom in the lymphatic system. 
 Early systemic symptoms: collapse (hypotension, shock), 
nausea, vomiting, diarrhoea, severe headache, “heaviness” of 
the eyelids, inappropriate(pathological) drowsiness or early 
ptosis/ ophthalmoplegia. 
 Early spontaneous systemic bleeding. 
 Passage of dark brown/black urine. 
PHYSICAL EXAMINATION 
This should start with careful assessment of the site of the 
bite and signs of local envenoming. 
EXAMINATION OF THE BITTEN PART  
The extent of swelling, which is usually also the extent of 
tenderness to palpation (start proximally), should be recorded. 
Lymph nodes draining the limb should be palpated and overlying 
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ecchymoses and lymphangitic lines noted. A bitten limb may be 
tensely oedematous, cold, immobile and with impalpable arterial 
pulses.These appearances may suggest intravascular thrombosis, 
which is exceptionally rare after snake-bite, or a compartmental 
syndrome, which is uncommon. If possible, intracompartmental 
pressure should be measured and the blood flow and patency of 
arteries and veins assessed (e.g. by doppler ultrasound).Early signs 
of necrosis may include blistering, demarcated darkening (easily 
confused with bruising) or paleness of the skin, loss of sensation 
and a smell of putrefaction. 
GENERAL EXAMINATION  
Measure the blood pressure (sitting up and lying to detect a 
postural drop indicative of hypovolaemia) and heart rate. 
Examine the skin and mucous membranes for evidence of 
petechiae, purpura, discoid haemorrhages), ecchymoses and, in the 
conjunctivae, for haemorrhages and chemosis.Thoroughly examine 
the gingival sulci, using a torch and tongue depressor, as these may 
show the earliest evidence of spontaneous systemic bleeding. 
Examine the nose for epistaxis.Abdominal tenderness may suggest 
gastrointestinal or retroperitoneal bleeding.Loin (low back) pain 
and tenderness suggests acute renal ischaemia (Russell’s viper 
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bite). Intracranial haemorrhage is suggested by lateralising 
neurological signs, asymmetrical pupils, convulsions or impaired 
consciousness in the absence of respiratory or circulatory collapse. 
To exclude early neurotoxic envenoming, ask the patient to look up 
and observe whether the upper lids retract fully.Test eye 
movements for evidence of early external ophthalmoplegia. The 
muscles flexing the neck may be paralysed, giving the “broken neck 
sign”. 
Cardiac manifestation is assessed by heart rate,blood pressure 
both supine and sitting,auscultation for gallop,murmurs and lung 
signs. 
INVESTIGATIONS/LABORATORY TESTS 
 
20-MINUTE WHOLE BLOOD CLOTTING TEST (20WBCT) 
Place 2 ml of freshly sampled venous blood in a small, new or 
heat cleaned, dry, glass vessel. Leave undisturbed for 20 minutes at 
ambient temperature. Tip the vessel once. If the blood is still liquid 
(unclotted) and runs out, the patient has hypofibrinogenaemia 
(“incoagulable blood”) as a result of venom-induced consumption 
coagulopathy. In the South-East Asia region, incoagulable blood is 
diagnostic of a viper bite and rules out an elapid bite. 
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Haemoglobin concentration / Haematocrit: A transient 
increase indicates haemo concentration resulting from a generalized 
increase in capillary permeability (e.g. in Russell’s viper 
bite).Decrease reflects blood loss or intravascular haemolysis. 
Platelet count: This may be decreased in victims of 
envenoming by vipers. 
White blood cell count: An early neutrophil leucocytosis is 
evidence of systemic envenoming from any species. 
Blood film:Fragmented red cells (“helmet cell”, schistocytes) 
are seen whenthere is microangiopathichaemolysis. 
Biochemical abnormalities: Aminotransferases and muscle 
enzymes (creatine kinase, aldolase etc) will be elevated if there is 
severe local muscle damage or  particularly, if there is generalized 
muscle damage (sea snake, some krait, Sri Lankan and South Indian 
Russell’s viper bites).  
Mild hepatic dysfunction is reflected in slight increases in 
other serum enzymes. Bilirubin is elevated following massive 
extravasation of blood. Potassium, creatinine, urea or blood urea 
nitrogen levels are raised in the renal failure of Russell’s viper, 
hump-nosed viper bites and sea snakebites. 
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Early hyperkalaemia may be seen following extensive 
rhabdomyolysis in sea snake-bites. Bicarbonate will be low in 
metabolic acidosis (e.g. renal failure).  
ABG and pH: may show evidence of respiratory failure 
(neurotoxic envenoming) and acidaemia (respiratory or metabolic 
acidosis). 
Urine examination: The colour of the urine (pink, red, 
brown, black) should be noted and the urine should be tested by 
dipsticks for blood or haemoglobin or myoglobin.Red cell casts 
indicate glomerular bleeding.Massive proteinuria is an early sign of 
the generalized increase in capillary permeability in Russell’s viper 
envenoming and an early indicator of acute kidney injury 
ECG AND ECHO:To assess the cardiac rhythm and 
contractile function respectively. 
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ANTI SNAKE VENOM (ASV)  
Anti snake venom (ASV) in India is polyvalent i.e. it is 
effective against all the four common species; Russells viper 
(Daboia russelii), Common Cobra (Naja naja), Common Krait 
(Bungarus caeruleus) and Saw Scaled viper (Echis carinatus). 
There are no currently available monovalent ASVs primarily 
because there are no objective means of identifying the snake 
species,in the absence of dead snake. 
ASV ADMINISTRATION CRITERIA13 
ASV is a scarce, costly commodity and should only be 
administered when there are definite signs of envenomation. 
Unbound free flowing venom can only be neutralized when it is in  
the blood stream or tissue fluid.In addition ASV carries the risk of 
anaphylactic reactions and should not therefore be used 
unnecessarily. 
ASV should be administered ONLY if  a patient develops one 
or more of following signs and symptoms of envenomation. 
SYSTEMIC ENVENOMING 
 Evidence of coagulopathy: Primarily detected by 20 WBCT 
or visible spontaneous systemic bleeding, gums etc.  
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 Evidence of neurotoxicity: ptosis, external ophthalmoplegia, 
inability to lift the head etc.  
The above two methods of establishing systemic 
envenomation are the primary determinants.In the Indian context 
one of these two categories will be the sole determinant of whether 
ASV is administered to a patient or not.The other indications for 
ASV are 
 Cardiovascular abnormalities: Hypotension, shock, 
cardiac arrhythmia, abnormal ECG.  
 Acute kidney injury: oliguria/anuria, rising blood creatinine/ 
urea. 
 Haemoglobin /myoglobinuria:dark brown urine,urine 
dipsticks, other evidence of intravascular haemolysis or 
generalised rhabdomyolysis. 
 Persistent and severe vomiting or abdominal pain.  
CURRENT LOCAL  ENVENOMING 
 Severe current, local swelling involving more than half of the 
bitten limb (in the absence of a tourniquet). In the case of 
severe swelling after bites on the digits. 
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 Rapid extension of swelling(for example beyond the wrist or 
ankle within a few hours of bite on the  hands or feet). 
 Development of an enlarged tender lymph node draining the 
bitten limb. 
NO ASV TEST DOSE MUST BE ADMINISTERED 
Test doses have been shown to have no predictive value in 
detecting anaphlactoid or late serum reactions. 
ASV is recommended to be administered in the following 
initial dose:  
Neurotoxic/ Anti Haemostatic ( 8-10 vials) 
All ASV should be administered over 1 hour period. The 
patient should be closely monitored for 2 hours. 
NEUROTOXIC ENVENOMATION 
Neostigmine is an anticholinesterase that prolongs the life of 
acetylcholine and can therefore reverse respiratory failure and 
neurotoxic symptoms. It is particularly effective for post synaptic 
neurotoxins such as those of the Cobra.14,15 There is some doubt 
over its usefulness agaist presynaptic neurotoxin such as those of 
the Krait and Rusell viper.16 
 29
In the case of neurotoxic envenomation the Neostigmine test 
will be administered with a dose of  1.5 mg of neostigmine i.m 
along  with 0.6 mg of Atropine i.v. 
The patient should be closely monitored for 1 hr to determine 
if neostigmine is effective.  
The followingare useful objective methods to assess this: 
1) Single breath count  
2) Mm of Iris uncovered (Amount covered by the descending 
eyelid) 
3) Inter incisor distance  
4) Length of time upward gaze can be maintained 
5) FEV 1 or FVC (If available) 
REPEAT DOSES: ANTI HAEMOSTATIC 
In the case of anti haemostatic envenomation, the ASV 
strategy is based on a 6 hour time period.When the initial test is 
abnormal initial ASV dose will be given over 1 hour.  
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After 6 hours a further coagulation test should be performed 
and a further dose should be administered in the event of continued 
coagulation disturbance. 
This is due to inability of liver to replace clotting factors 
within 6 hours. WBCT and ASV dosing should be done on 6 hourly 
basis until coagulation is restored. 
The repeat dose should be 5-10 vials of ASV i.e. half to one 
full dose of the original dose. 
REPEAT DOSES: NEUROTOXIC 
The ASV regime relating to neurotoxic envenomation has 
caused considerable confusion. If the initial dose has been 
unsuccessful in reducing the symptoms or if the symptom have 
worsened or if the patient has gone into respiratory failure then a 
further dose should be administered, after 1-2 hours. At this point 
the patient should be re-assessed. If the symptoms have not 
improved or worsened second dose of ASV can be given. This dose 
should be the same as the initial dose, i.e. if 10 vials were given 
initially then 10 vials should be repeated for a second dose and then 
ASV is discontinued. 20 vials is the maximum dose that should be 
given to neurotoxically envenomed patient. 
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HYPOTENSION  AND PULMONARY EDEMA 
Hypotension can have a number of causes, particularly loss of 
circulating volume due to haemorrhage, vasodilation due to the 
action of the venom or direct effects on the heart. Treatment is by 
means of plasma expanders.Pulmonary edema is managed by 
diuretics and ventilator support. 
ANTIVENOM REACTIONS: 
ASV reactions manifest as  
(1)Early anaphylactic reactions, 
(2)Pyrogenic reactions, 
(3)Late Serum sickness like reactions. 
 
ASV should be stopped at the earliest sign of a reaction.  
Epinephrine(0.1% solution) is the effective treatment for early 
anaphylactic and pyrogenic antivenom reactions.In patients with early 
anaphylactic and pyrogenic antivenom reactions: Epinephrine is given 
intramuscularly (into upper lateral thigh) in an initial dose of 0.5 mg for 
adults and 0.01 mg/kg body weight for children. 
Late serum sickness like reactions are treated with oral antihistamines,if 
refractory with oral steroids for 5-7 days. 
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MATERIALS AND METHODS  
MATERIALS 
All cases of Snake Bite coming to the hospital will be 
admitted and form the subjects of the study. 
DESIGN OF STUDY 
Prospective study 
Sample size : 100  
Human study or not : Yes, it involves Humans only 
Ethical clearance status :  Obtained 
Period Of Study:7 Months 
PLACE OF STUDY 
Poison Control, Training& Research Centre, Rajiv Gandhi 
Government General Hospital, Madras Medical College, Chennai-3. 
METHODS 
1) Inclusion criteria: 
 All admitted cases of snake bite will be evaluated to 
assess poisonous status. 
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2) Exclusion criteria:  
 Those with existing cardiac   disease, children, pregnant 
women, immune suppressed persons, those with any 
other chronic illness will be excluded from the study.  
3) Informed consent will be obtained from each case included 
for the study. 
4) Poisonous cases will be grouped according to Elapidae, 
Viperidae or other bites by syndromic approach. 
5) Snakes will be identified when it is brought by the 
victim/relatives. 
6) Details will be documented in a proforma (enclosed). 
7) Laboratory investigations will be done as in 
proforma(enclosed). 
8) Additional biochemical parameters likely to influence the 
cardiac function. 
9) Cardiac screening  by ECG and ECHO will be carried at 
Poison control, Training & Research Centre, GGH, Chennai. 
ECG, ECHO will be  done on DAY 1, 3 and repeated 
whenever required. 
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10) Patients will be followed up daily while in the hospital. 
11) Patients will be provided appropriate treatment. 
12) Follow up :Cases with cardiac involvement will be followed 
up after 4 weeks by ECG and ECHO. 
13) Data will be entered into the excel sheet of the computer. 
14) Data will be analysed  using SPSS package. 
 35
RESULTS AND OBSERVATIONS 
SEX DISTRIBUTION
MALE
FEMALE
 
TABLE 1: 
SEX PERCENTAGE (%) 
MALE 74 
FEMALE 26 
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TABLE 2: 
AGE GROUP (IN YEARS) PERCENTAGE (%) 
< 20 13 
21 - 30 26 
31 – 40 25 
41 – 50 18 
51 – 60 12 
> 60 6 
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TABLE 3: 
 
 
SITE OF BITE PERCENTAGE (%) 
UPPER LIMB 36 
LOWER LIMB 56 
OTHERS 8 
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TABLE 4: 
TIME  TO   REACH  HOSPITAL PERCENTAGE (%) 
< 2 HOURS 78 
2 – 4 HOURS 11 
>4 HOURS 11 
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TABLE  5: 
SPECIES  OF  SNAKE PERCENTAGE 
COBRA 28 
COMMON KRAIT 16 
RUSELL VIPER 42 
SAW SCALE VIPER 14 
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TABLE 6: 
TREATMENT  BEFORE  ADMISSION PERCENTAGE (%) 
HOSPITAL 43 
NATIVE 04 
TOURNIQUET TIED 28 
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CLINICAL FEATURES  AT THE 
TIME OF ADMISSION
 
TABLE 7: 
CLINICAL  FEATURES   ON  ADMISSION FREQUENCY 
ALTERED  CONSIOUS LEVEL 04 
BRADYCARDIA 09 
TACHYCARDIA 12 
HYPOTENSION 09 
HYPERTENSION 09 
TACHYPNOEA 26 
BRADYPNOEA 02 
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TABLE 8: NEUROTOXICITY 
MANIFESTATIONS PERCENTAGE (%) 
PTOSIS 55 
DIPLOPIA 45 
RESPIRATORY PARALYSIS 25 
NEUROTOXICITY+HEMOTOXICITY 12 
NEUROTOXICITY + LOCAL 
ENVENOMATION 
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TABLE 9: HEMOTOXICITY 
MANIFESTATIONS PERCENTAGE (%) 
WBCT > 20 MINS 52 
BLEEDING GUMS 7 
HEMATURIA 3 
UGI BLEED 0 
NEUROTOXICITY+HEMOTOXICITY 12 
HEMOTOXICITY+LOCAL 43 
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TABLE 10: 
CARDIAC MANIFESTATIONS FREQUENCY 
HYPOTENSION 09 
HYPERTENSION 09 
BRADYCARDIA 11 
TACHYCARDIA 12 
PULMONARY EDEMA 02 
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TABLE 11: CARDIAC  MANIFESTATION  IN  THE  FORM  
OF HYPOTENSION 
MANIFESTATION PERCENTAGE 
NEUROTOXICITY 7 
WBCT > 20 MINS 2 
TOTAL  9 
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TABLE 12: CARDIAC  INVOVEMENT  IN THE  FORM  OF  
BRADYCARDIA 
MANIFESTATION PERCENTAGE 
NEUROTOXICITY 10 
WBCT >20  MINS 1 
TOTAL 11 
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TABLE  13: 
 NORMAL ABNORMAL 
ECG 65 35 
ECHO 98 02 
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TABLE 14: 
ECG  CHANGES PERCENTAGE (%) RECOVERED DEATH
NORMAL 65 65  
SINUS  
TACHYCARDIA 
12 12  
SINUS  
BRADYCARDIA 
11 10 1 
FIRST DEGREE AV 
BLOCK 
1 1  
SECOND DEGREE 
AV BLOCK 
0 0  
T INVERSION IN 
PRECORDIAL 
LEADS 
8 8  
POOR R WAVE 
PROGRESSION IN 
PRECORDIAL 
LEADS 
3 3  
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TABLE 15: 
TREATMENT PERCENTAGE 
ASV 100 
MECHANICAL VENTILATION 27 
VASOPRESSORS 9 
DIALYSIS 3 
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MORTALITY: 
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RESULTS 
 The present study observed that 26 per cent of patients of 
snake bite were in 2nd and 3rd decades of life,74% males and 26% 
females,56%of bites occurred in the lower extremities and 78 % of 
victims reached a healthcare facility in less than 2 hours.Viperine 
snake bite occurred in 56 per cent and Elapide snake bite occurred  
in 44 per cent of cases. 
 Cardiac involvement  manifested  in  the form  of  alterations 
in the heart  rate,blood pressure and  electrocardiographic  changes. 
The disturbance in heart rate was seen  in 23% per cent.Out 
of the 100 patients tachycardia was present in 12 per cent and 
bradycardia in 11  per cent of  cases. 
Hypertension was found in 9 per cent, hypotension in 9 per 
cent.Two patients had evidence of pulmonary edema. 
Electrocardiography revealed changes in the form of sinus 
tachycardia(12%),sinus bradycardia (11%),myocardial ischemia 
(8%), and Poor R wave progression (3%). 
One patient had electrocardiographic features of global T 
wave inversion and echocardiographic features of apical 
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hypokinesia suggestive of cardiomyopathy which reversed after a 
month. 
The mortality rate was 5 per centof which 4 patients had 
neurotoxic features,1 patient had hemotoxic features and other 2 
had evidence of pulmonary edema with abnormal 
electrocardiographic changes.  
Postmortem was conducted in one patient.Section from heart 
showed normal cardiac muscle fibrosis with intervening interstium 
showing areas of hemorrhage. No evidence of coagulation necrosis is 
seen. Section from aorta shows thickened media and adventitia showing 
congested blood vessels. 
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DISCUSSION 
The present  study was conducted in 100 cases of snake bite to     
understand the pattern of cardiac involvement and to render help   
in the management of the problems arising out of them.All    
patients were subjected to routine clinical examination and    
specific investigations. 
EPIDEMIOLOGY OF SNAKE BITE 
Age  and Sex Distribution: 
In this  series  of 100 cases ,the number of the patients below 
20 years of age were(13%), between 21-30 were (26%) ,between 
31-40  were (25%) ,between 41-50  were (18%) ,above 50 
(18%)).In this series males constituted about 74% and females 
about 26%. In study by Nayak et al,17  57% patients were in the  
2nd  and 3rd decade of life. The series reported in this study had the 
similar pattern of age group affection. This young age group 
affected by exposure forms the viable entity of any population both 
in terms of procurement and productivity. This case study and the 
case reports mentioned above throw light on the target age group 
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for educative and preventive programs to reduce the incidence of 
snake bite. 
SITE OF BITE AND SPECIES OF SNAKE: 
In this series 36% of bites occurred in the upper extremities, 
56% of bites occurred in the lower extremities,8% of bites occurred 
in other  areas such as head, trunk etc. Most bite in areas other than 
extremities occurred in Krait bites. Among 100 patients species 
identification was done depending upon the dead snake brought by 
the victims or by clinical manifestations using the syndromic 
approach. Cobra bite occurred in 28%, Common krait bite occurred 
in 16%, Russell viper bite occurred in 42%, Saw scaled viper bite 
occurred in 14%. In study by Nayak et al 17 Viperine snake bites 
occurred in 93 per cent and elapide snake bite in 7 per cent of 
cases. 
TIME TO REACH HOSPITAL AND TREATMENT BEFORE 
ADMISSION 
In this series 78% of victims arrived at hospital within 2 
hours, 11% arrived between 2-4 hours and 11% reached after 4 
hours. In these 100 cases 43 cases were treated and referred from 
nearby GH and PHC’s belonging to five districts (Chennai, 
Thiruvallur, Kancheepuram, Villupuram and  Vellore).4% of 
patients  had native treatment and 28% had tourniquet tied above 
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the site of bite, which may be complicating factor for local 
envenomation which was present in 78% of patients in this study. 
Tourniquet use is contraindicated for use in India for the following 
reasons because of risk of  ischemia and loss of the limb, increased  
risk of  necrosis with 4/5 of the medically significant snakes of 
India, increased risk of massive neurotoxic blockade when 
tourniquet is release, risk of embolism if used in viper bites. 
      In addition,there is a danger of hypotension due to vasodilatory  
effects  of  venom  when  the  tourniquet  is  released.They give  
patients a false sense of security, which encourages them to delay  
their journey to hospital. In the study by Nayaket al17 seventy-six  
per cent of the patients presented within 24 hours of the bite. 
CLINICAL FEATURES AT THE TIME OF ADMISSION: 
Among 100patient 4% presented with altered sensorium,12% 
had tachycardia,9% had bradycardia.Hypertension24  was present in 
9% and hypotension  in  9%.26% of patients  were tachypnoeic and 
9 % of patients were bradypnoeic. In the study by Nayak et al17 
tachycardia was found in  36.7 per cent and bradycardia in 10 per 
cent cases. 
 56
Hypertension was found in 6.7 per cent, hypotension in 16.7 
per cent. Thirty per cent of patients had gallop rhythm. In our study 
two patients  had evidence of pulmonary edema 41 with bilateral end 
inspiratory fine crepitations in both lung bases and no patient in  
our  study had gallop rhythm. 
TOXIC MANIFESTATIONS 
Neurotoxicity was present in 55%,neurotoxicity and 
hemotoxicity combined in 12% and neurotoxicity and local 
envenomation  combined in 35%.Hemotoxicity was present in 52% 
of patients in the form of prolonged WBCT >20 Mins. Other 
bleeding manifestations like bleeding gums and hematuria were 
present in 7% and 3% of patients respectively.Combined 
hemotoxicity and local envenomation were present in 43% of 
patients. The higher percentage of combination of neurotoxic, 
hemotoxic  and  local envenomation was due to the higher 
percentage of Rusell viper bites in this  series. 
CARDIOVASCULAR  MANIFESTATIONS 
Among 9% of patients with hypotension neurotoxicity was 
present in 7% and hemotoxicity was present in 2%.Among 11% of 
patients with bradycardia 11% had neurotoxic manifestations 
and1% had both neuro and hemotoxic manifestations. In this series 
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of 100,2 patients presented with features of acute pulmonary 
edema. 
Pulmonary edema in snake bite may be secondary to 
myocarditis,35,36 non cardiogenic pulmonary oedema secondary to 
the ASV used.26 However, thisphenomenon generally occurs within 
six hours after  Antivenin administration. The use  of  
cardiodepressive drugs, e.g. benzodiazepine for sedation while 
performing bronchoscopy can also trigger pulmonary oedema. 
Other contributory causes, e.g. ischaemic insult to the heart 
secondary to hypoxia from delayed intubation, aspiration/mucous 
plugging with poor ventilation, can contribute to the causation of 
pulmonary oedema in patients with snake bites. The mechanism of 
cardiac involvement in neurotoxic snake bites is not clear18 but is 
likely to be due to one of the myriad toxins seen in snake venom, 
which can cause morphological changes, enzyme alterations, ultra 
structural disturbances and  genetic  alterations of the myocardial 
tissue. In a recent experimental study, analysis of gene expression 
profiles in mice in response to cobra venom treatment revealed 203 
genes in the heart, brain, kidney, liver and lung whose expressions 
were altered by at least three-fold.19,21  Of these, 50%  were 
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differentially expressed in the heart, and included genes involved in 
inflammation, apoptosis, ion transport and energy metabolism.25,28 
ECG  FEATURES: 
Among the 100 patients, the significant ECG abnormalities 
were found in 35%, 65% had normal rate and rhythm.Of the 
35%,11% had Sinus Bradycardia, 12% had Sinus Tachycardia,1% 
had First degree Heart block. T wave inversion in precordial leads 
was present in 8% and  Poor R wave progression in precordial leads 
was present in 3% of patients. The ECG changes were transient and 
recovered after treatment of snake bite. Ventricular ectopics and 
Bundle branch blocks were not found in our study38,39 .In study by 
Nayaketal17electrocardiographic changes were sinus tachycardia, 
sinus arrhythmia (6.6%), sinus bradycardia (10%), tall T-wave in 
V2 (3.3%), pattern suggestive of acute anterior wall infarction with 
reciprocal changes (3.3%), myocardial ischemia (10%), non-
specific ST-T changes (16.7%) and atrioventricular block 
(3.3%).Acute myocardial infarction complicating snake bite had 
been published as case reports which was not found in our 
series.29,30,31,33 
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ECG showing global T wave inversion in a patient with snake 
bite 
 
ECG showing non specific ST-T changes in a patient with snake bite 
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ECHOCARDIOGRAPHY 
Among 100 patients, 2 persons had hypokinesia of apical 
segment which recovered after a month. 
RENAL FUNCTION TEST 
In this series renal function test was abnormal in 10 patients 
of these dialysis was done in 3 patients. All patients with renal 
abnormalities had prolonged WBCT.32 
SGOT AND CPK 
In our series AST was elevated in 28% and CPK was elevated 
in 48% of patients. In study by Nayak et al17 elevated AST titres 
were found in 10% of patients. 
TREATMENT 
All 100 patients received Anti Snake Venom, 27% were 
mechanically ventilated, 9% were treated with vasopressors and 3% had 
dialysis. Patients with  pulmonary edema were treated with diuretics and 
mechanical ventilation.On an average patients with neurotoxic 
envenomation had 16 vials of ASV and patients with hemotoxic 
envenomation had 18 vials of ASV. 
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MORTALITY 
Overall mortality in our study was 5%. In the five patients who 
died in our study, 4 patients had neurotoxic envenomation and 1 patient 
had neurotoxic and hemotoxic manifestations with cerebral infarction.34 
Of the 5% of death cases 2 patients had bradycardia,2 patients had 
features of pulmonary edema and 3 patients had hypotension along with 
neurotoxic and hemotoxic features.This in contrast to study by Nayak et 
al 17 were the mortality rate was 10% and all these patients had bleeding 
manifestations and abnormal electrocardiograms. 
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CONCLUSION 
1) Snake bite is more common in 20 – 40 yrs age group in this 
study. 
2) In our study Viperine bites were more common than Elapide 
bites but have a better prognosis. 
3) Mortality was more among patients with neurotoxic 
envenomation probably due to associated autonomic 
instability.20,23 
4) Cardiac involvement in snake envenomation can manifest  
clinically in the form of autonomic dysfunction  with  
hypertension or hypotension, tachycardia or bradycardia, 
features  of  heart failure.41 
5) Electrocardiographic changes in snake envenomation include 
cardiac rhythm disturbances and features of myocardial 
ischemia. 
6) Prognosis was poor among patients who present with 
hypotension and pulmonary edema. 
7) Treatment in addition to ASV requires Vasopressors and 
diuretics in these group of patients. 
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STRENGTHS AND LIMITATIONS 
1) Number of patients in the study were thrice than the previous 
studies in cardiac manifestations in snake bite. 
2) Cardiac manifestations were reported more in Elapid bites as 
compared to previous studies. 
3) The limitations were single center study and children were 
not included.  
4) Specific cardiac markers of  myocardial injury was not done. 
5) Novel echocardiographic Doppler techniques for  myocardial 
injury was not done. 
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RECOMMENDATIONS 
1) No specific treatment apart from snake antivenom is required 
for the cardiac involvement.  
2) Supportive measures, such as management of pulmonary 
oedema with diuretics and change in ventilator strategy and 
treatment of dysrhythmia, may be required in specific cases. 
3) Cardiac complications should be thought of when abnormal 
findings ensue, monitoring the patient with serial ECGs and 
cardiac enzymes is necessary. 
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                        ANNEXURES 
                    ABBREVIATIONS 
ABG – Arterial blood gas analysis 
AST – Aspartate Transaminase 
ASV – Anti Snake Venom 
BP – Blood Pressure 
CPK – Creatinine Phosphokinase 
FVC - Forced vital capacity 
ECG - Electrocardiogram 
ECHO – Echocardiography 
SBC – Single Breath Count 
WBCT – Whole Blood Clotting time 
WHO – World Health Organisation 
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PROFORMA 
POISON CONTROL, TRAINING AND RESEARCH CENTRE, 
RGGGH, CHENNAI. 
Name:                                      I.P No:                       DOA:                   
DOD: 
Age :  Locality:                    Occupation:    
Gender: Male/Female            Ht:     cm      Wt:      kg            BMI: 
Referral: 
DETAILS ABOUT SNAKE BITE: 
Time Snake Bite:         am/pm 
Site of bite: UL/LL/R/L  - Other areas specify……….. 
Time taken to reach the hospital: 
Tourniquet tied: yes/no.  If yes mention the duration………. 
Nature of snake: Cobra/Krait/Russell /Saw scaled viper/others 
TREATMENT BEFORE ADMISSION: HOSPITAL/NATIVE 
(specify details) 
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CLINICAL  EXAMINATION 
VITALS: 
HR- 
BLOOD PRESSURE-supine:                       sitting: 
RESPIRATORY RATE- 
TEMPERATURE- 
CVS: 
RS: 
ABDOMEN: 
NEUROLOGICAL: 
LABORATORY INVESTIGATIONS: 
BIOCHEMICAL PARAMETERS 
RFT Day-1 Day -3  
1. Sugar     
2. Urea     
3. Creatinine     
4. Sodium     
5. Potassium     
  
 75
  Cardiac markers 
1. SGOT 
2. CPK 
3. CPKMB 
4. LDH 
 LIPID PROFILE 
1. Total Cholesterol 
2. TGL 
3. HDL 
         USG ABDOMEN: 
                                          DAY 1                DAY 3            
ELECTROCARDIOGRAM: 
ECHOCARDIOGRAPHY: 
TREATMENT AND FOLLOW UP: 
CONDITION ON DISCHARGE : RECOVERED/EXPIRED 
If expired with informed consent of relatives,victims heart 
will be harvested and macroscopic examination and microscopic 
examination of cardiac muscle biopsy by light microscopy will be 
done. 
 
 
1 20 M 2 YES YES NO 92 150/90
2 25 M 2 YES YES YES NO 56 90/70
3 11 M 2 YES YES YES NO 130 90/68
4 27 M 2 YES YES YES NO 78 110/70
5 39 M 2‐4 HRS YES YES YES YES 79 130/100
6 38 M 2 YES YES YES NO 60 120/80
7 16 M 2‐4 HRS YES YES YES NO 90 110/70
8 30 M 2 YES YES YES NO 82 110/70
9 47 F 2 YES YES YES YES NO 60 150/90
10 30 F 2‐4 HRS YES YES NO 56 110/76
11 70 F 2 YES YES YES YES 100 110/70
12 15 M 2 YES YES YES NO 100 80/60
13 47 M 2 YES YES YES NO 80 130/80
14 10 F 4 YES YES YES YES 108 108/70
15 75 M 2 YES YES NO 90 150/100
16 14 M 2 YES YES YES YES 94 120/70
17 65 M 2 YES YES 75 140/90
18 65 M 2 YES YES NO 78 100/70
19 25 M 4 YES YES YES NO 64 130/86
20 22 M 2 YES YES NO 96 100/70
21 54 M 2 YES YES YES YES 90 110/70
22 40 F 2 YES YES YES YES 84 110/70
23 70 M 4 YES YES YES YES 118 80/50
24 43 M 2 YES YES YES YES 80 110/70
25 18 F 2 YES YES YES YES 80 110/70
26 20 M 2 YES YES YES 90 110/86
27 32 M 2 YES YES YES 90 110/76
28 30 M 4 YES YES NO 58 120/70
29 40 M 2 YES YES YES NO 86 110/80
30 24 M 2 YES YES YES NO 72 110/70
31 39 M 2 YES YES NO 82 110/80
32 45 M 2 YES YES NO 120 90/60
33 56 F 2 YES YES NO 56 100/60
34 25 M 2 YES YES NO 86 140/90
35 46 M 4 YES YES YES 78 130/86
36 16 M 2 YES YES YES NO 86 100/70
37 43 F 2 YES YES YES NO 90 140/90
38 35 M 2 YES YES NO 86 120/80
39 26 F 2 YES YES YES 86 120/70
40 60 F 2 YES YES NO 78 106/80
COBRA KRAIT RUSSELL VIPER SAW SCALED VIPER HR BPDM SHT HEART DIS NATIVES.No Age Sex Duration UL   LL OTHER HOSPITAL TOURNIQUET
41 25 M 2‐4 HRS YES YES YES NO 82 110/78
42 62 M 2 YES YES NO 89 140/90
43 39 M 2 YES YES YES NO 93 80/60
44 48 F 2 YES YES YES NO 86 140/90
45 16 F 2 YES YES YES NO 96 80/60
46 24 M 2 YES YES YES 86 120/80
47 36 M 2 YES YES YES NO 95 108/76
48 49 M 2 YES YES YES 82 110/80
49 34 F 2 YES YES YES NO 85 140/90
50 31 F 4 YES YES YES 72 120/80
51 25 M 2 YES YES NO 86 110/80
52 19 F 2 YES YES NO 86 110/80
53 23 M 2 YES YES YES YES 76 110/76
54 47 M 2 YES YES NO 56 110/76
55 34 M 2 YES YES YES 79 130/86
56 29 M 2 YES YES NO 86 110/80
57 38 M 2 YES YES NO 96 130/86
58 56 F 2‐4 HRS YES YES NO 86 130/80
59 38 M 2 YES YES YES NO 102 120/80
60 53 M 2 YES YES YES NO 98 150/90
61 47 M 2 YES YES YES YES 76 130/80
62 52 M 2 YES YES NO NO 98 140/90
63 24 M 2‐4 HRS YES YES NO YES 84 110/70
64 26 F 2 YES YES NO YES 95 120/80
65 35 M 2 YES YES YES YES 79 110/78
66 31 M 2 YES YES NO NO 86 140/90
67 29 M 2 YES YES NO NO 82 130/80
68 16 F 2 YES YES YES NO 98 120/80
69 54 M 2 YES YES YES NO NO 85 140/90
70 47 M 4 YES YES NO 58 110/80
71 41 F 2‐4 HRS YES YES YES 92 110/80
72 31 M 4 YES YES YES NO 80 130/80
73 38 M 4 YES YES NO 94 120/80
74 40 M 2 YES YES NO 75 140/90
75 35 M 2 YES YES YES NO 86 120/76
76 45 M 4 YES YES YES NO 78 110/80
77 44 M 2‐4 HRS YES YES NO 85 140/90
78 52 M 2 YES YES NO 88 130/80
79 34 F 2 YES YES YES NO 98 110/86
80 27 M 2 YES YES YES 84 120/80
81 36 M 2 YES YES NO 70 110/8o
82 28 M 2 YES YES YES NO 82 110/80
83 45 M 2 YES YES YES YES 98 130/80
84 57 M 2 YES YES NO 104 140/90
85 39 M 2‐4 HRS YES YES YES 100 130/80
86 29 F 2 YES YES NO 86 110/80
87 51 F 2 YES YES NO 98 120/90
88 43 M 2 YES YES NO 102 130/80
89 55 M 2 YES YES NO 90 120/80
90 41 F 2‐4 HRS YES YES NO 58 130/80
91 27 F 4 YES YES YES NO 89 130/80
92 38 M 2 YES YES NO 88 120/80
93 22 M 2 YES YES YES NO 102 120/86
94 30 M 2 YES YES YES NO 78 120/80
95 29 M 2 YES YES YES NO 82 110/70
96 24 F 2 YES YES YES NO 130 80/60
97 16 M 2 YES YES YES YES 140 120/80
98 30 F 2 YES YES NO NO 58 80/60
99 52 M 2‐4 HRS YES YES YES NO 96 150/90
100 48 M 2 YES YES NO NO 102 70/50
PTOSIS DIPLOPIA RES PARALYSIS NEOSTIGMINE WBCT BLEEDING GUMS UGI BLEED HEMATURIA MURMURS            BASAL CREPTS
20 NO NO NO 20MINS NO NO NO YES NO NO
20 YES YES NO NOT RESPONSIVE N NO NO NO NO NO NO
24 YES YES YES NOT RESPONSIVE N NO NO NO NO NO NO
26 YES YES YES RESPONSIVE N NO NO NO YES NO NO
20 YES YES NO N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
18 YES NO NO N NO NO NO YES NO NO
19 YES NO NO N NO NO NO YES NO NO
18 YES NO NO N NO NO NO YES NO NO
26 YES YES YES NOTRESPONSIVE N NO NO NO NO NO NO
20 YES YES NO N NO NO NO YES NO NO
25 YES YES YES NOTRESPONSIVE 20MINS NO NO NO YES NO NO
18 YES YES NO N NO NO NO YES NO NO
19 YES NO NO N NO NO NO YES NO NO
25 YES YES YES NOTRESPONSIVE N NO NO NO NO NO BASAL CREPTS
22 YES YES NO 20MINS NO NO NO YES NO NO
20 YES NO NO 20MINS NO NO NO YES NO NO
18 NO NO NO N NO NO NO YES NO NO
25 YES YES YES 20MINS NO NO YES YES NO NO
18 NO NO NO 20MINS NO NO NO NO NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
19 NO NO NO 20MINS NO NO NO YES NO NO
24 YES YES NO NOTRESPONSIVE 20MINS NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
19 NO NO NO 20MINS NO NO NO YES NO NO
18 YES YES NO N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
16 YES YES NO N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
26 YES YES NO N NO NO NO NO NO BASAL CREPITS
25 YES YES YES N NO NO NO NO NO NO
18 YES NO NO 20MINS NO NO YES YES NO NO
16 NO NO NO 20MINS NO NO NO YES NO NO
24 YES YES YES N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO NO NO NO
18 NO NO NO 20MINS YES NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO NO NO NO
LOCAL ENVENOMATION CARDIO VASCULAR AND RESPIRATORYNEUROTOXIC HEMOTOXICRR
20 YES YES NO N NO NO NO NO NO NO
20 NO NO NO 20MINS NO NO NO YES NO NO
24 YES YES YES N NO NO NO NO NO BASAL CREPITS
20 NO NO NO 20MINS NO NO NO YES NO NO
25 YES YES YES N NO NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO YES NO NO
20 YES YES NO 20MINS YES NO NO YES NO NO
19 NO NO NO N NO NO NO YES NO NO
26 YES YES YES N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO NO NO NO
22 YES YES NO 20MINS NO NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO YES NO NO
24 YES YES YES N NO NO NO NO NO NO
20 NO NO NO N NO NO NO YES NO NO
20 YES YES NO N NO NO NO NO NO NO
20 YES YES NO N NO NO NO YES NO NO
20 YES YES NO N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
24 YES YES YES N NO NO NO NO NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
25 YES YES YES N NO NO NO YES NO NO
18 NO NO NO 20MINS YES NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
18 YES NO NO 20MINS YES NO YES YES NO NO
20 YES NO NO N NO NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO NO NO NO
28 YES YES YES N NO NO NO NO NO NO
17 NO NO NO 20MINS NO NO NO NO NO NO
24 YES YES YES N NO NO NO NO NO NO
20 NO NO NO 20MINS NO NO NO NO NO NO
18 YES YES NO N NO NO NO NO NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
20 NO NO NO N NO NO NO YES NO NO
19 NO NO NO 20MINS NO NO NO NO NO NO
24 YES YES YES N NO NO NO NO NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
18 YES YES NO N NO NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO YES NO NO
18 NO NO NO 20MINS YES NO NO YES NO NO
23 YES YES YES N NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
20 NO NO NO 20MINS NO NO NO YES NO NO
24 YES YES YES N NO NO NO YES NO NO
20 YES NO NO 20MINS NO NO NO YES NO NO
20 YES YES NO N NO NO NO YES NO NO
20 YES NO NO 20MINS YES NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
18 NO NO NO 20MINS NO NO NO YES NO NO
27 YES YES YES N NO NO NO NO NO NO
20 YES YES NO 20MINS NO NO NO YES NO NO
18 NO NO NO N NO NO NO YES NO NO
24 YES YES NO N NO NO NO NO NO NO
18 N NO NO 20MINS YES NO NO YES NO NO
18 N NO NO 20MINS NO NO NO NO NO NO
26 YES YES YES N NO NO NO NO NO NO
25 YES YES YES N NO NO NO YES NO NO
29 YES YES YES N NO NO NO NO NO BASAL CREPITS
24 YES YES YES N NO NO NO YES NO NO
25 YES YES YES N NO NO NO NO NO NO
DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3
1 80 94 154 40 8.5 2 134 140 4.1 3.2 145 156 250 200 708 250
2 119 96 30 32 0.8 0.8 142 140 3.9 4 24 40 120 130 200 200
3 240 110 25 25 0.7 0.7 142 132 3.6 3.5 34 36 110 120 140 120
4 145 140 36 36 1.2 1.3 135 130 4 3.8 42 46 186 183 140 146
5 90 96 32 30 0.9 0.9 140 140 3.6 3.8 154 126 126 120 130 130
6 120 136 26 28 0.9 0.9 147 140 3.8 3.6 44 46 120 114 126 125
7 120 110 18 20 0.8 0.8 134 130 3.3 3.3 129 123 120 140 120 100
8 159 178 37 47 1.1 1.3 150 146 3.3 3.3 256 200 356 250 1896 500
9 86 93 22 25 0.8 0.8 155 136 3.7 3.5 30 36 88 86 733 440
10 82 96 19 16 0.8 0.8 140 136 2.2 3.3 21 26 84 86 123 120
11 156 140 38 36 2 1.8 145 136 3.2 3.3 148 140 86 8 145 142
12 108 120 31 32 0.9 0.9 144 130 2.8 3.6 21 26 100 100 156 200
13 260 126 65 43 2.1 1.6 147 145 4.4 4 178 170 200 156 245 196
14 101 100 24 24 0.9 0.8 149 145 3.8 3.6 28 26 145 152 125 156
15 140 150 21 23 0.9 0.9 140 140 3.7 3 24 26 256 200 152 125
16 125 79 45 46 1 1 147 139 4.2 4.2 99 101 987 356 298 200
17 152 117 53 23 1.2 1 148 144 3.2 3.3 72 82 1395 588 767 608
18 172 84 56 43 1.3 1.2 140 144 3.8 4.2 110 156 1777 536 614 516
19 90 62 152 144 5.8 7.2 139 144 4.7 5.4 246 256 562 456 156 125
20 255 152 54 46 1.2 0.8 144 135 2.8 3.6 53 56 156 123 142 142
21 145 151 56 46 1.5 1.4 145 146 3.2 3.6 118 115 4260 1520 1280 456
22 258 126 40 39 0.8 0.8 144 145 3.2 3.3 256 220 145 125 156 256
23 87 56 119 98 2.3 1.3 145 148 2.7 4.1 176 145 5390 1554 1503 147
24 91 106 30 30 1.2 0.9 143 142 3.7 3.6 54 54 542 256 145 145
25 80 86 50 42 0.9 0.9 144 145 3.7 3.7 640 256 125 144 120 110
26 108 145 23 26 1 1 145 142 4.1 4 152 100 145 145 120 120
27 125 120 25 26 0.8 0.9 142 140 4.2 4 45 46 142 152 120 145
28 80 86 28 26 0.8 0.8 142 142 4 4 62 63 984 456 1272 1200
29 148 142 21 25 0.9 0.9 150 145 3.3 3.2 45 42 456 254 145 125
30 123 120 19 20 0.9 0.8 133 132 2.9 3.3 34 34 256 250 145 125
31 100 120 20 26 0.8 0.8 144 126 4.5 4 32 30 122 126 120 102
32 156 125 36 35 1.2 1 145 136 4.5 4.2 46 42 2564 1526 456 125
33 256 120 25 26 2 1.2 145 136 4.2 4 45 56 4256 1263 789 458
34 154 120 25 26 2 1 145 135 3.2 3.3 45 42 1256 1234 456 256
35 152 117 53 23 1.2 1 148 144 3.2 3.3 72 82 1395 588 767 608
NO
POTASSIUMSUGAR UREA SODIUM
RFT
LDHCREATININE
CARDIAC MARKERS
SGOT CPK 
DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3
NO
POTASSIUMSUGAR UREA SODIUM
RFT
LDHCREATININE
CARDIAC MARKERS
SGOT CPK 
36 120 110 42 30 0.6 0.8 125 130 4.2 3.2 25 26 456 256 452 125
37 156 142 40 38 1.2 1 145 142 3.3 3 45 42 526 253 125 123
38 145 142 30 32 0.8 1 126 130 4.2 4 45 52 456 125 124 103
39 120 130 40 30 1.2 1 132 126 3.2 3 26 26 562 354 125 120
40 96 90 42 40 1.2 1 123 123 3.3 3 35 36 256 245 136 130
41 152 102 30 30 1.2 1 126 1235 4 3.3 25 25 456 254 145 112
42 145 120 36 35 1.5 1.3 123 156 3.3 3.9 24 40 236 124 111 112
43 125 111 30 36 0.8 1.2 153 126 3 3.1 24 26 4561 2561 458 246
44 236 200 40 36 1 1 142 136 3.2 3 26 25 245 200 456 245
45 123 120 40 46 1.2 2 145 146 4.2 4 45 78 452 400 457 568
46 125 120 30 30 1 1 136 135 3.6 3.3 25 24 246 240 158 168
47 156 124 76 46 2.6 1.2 145 123 5.4 4 89 102 2568 241 458 365
48 125 120 30 32 1 1.2 132 125 3 3 45 25 421 400 145 125
49 120 96 50 38 2 1 125 125 3 3.6 45 24 298 265 123 100
50 110 86 24 26 1 0.8 112 122 2.6 3.5 24 21 214 236 102 100
51 111 90 25 25 1 0.8 125 126 3 3.3 24 22 126 130 124 122
52 96 120 30 30 1.2 1 142 135 3.2 3 89 790 654 356 300 142
53 156 140 38 36 2 1.8 145 136 3.2 3.3 148 140 86 126 145 142
54 108 120 31 32 0.9 0.9 144 130 2.8 3.6 21 26 100 100 156 200
55 145 140 36 36 1.2 1.3 135 130 4 3.8 42 46 186 183 140 146
56 156 140 38 36 2 1.8 145 136 3.2 3.3 148 140 86 136 145 142
57 130 125 36 32 1 1 125 126 3.3 3 25 29 200 200 130 126
58 140 120 45 35 1 1.2 135 134 3.3 3 46 45 458 251 142 140
59 100 120 20 26 0.8 0.8 144 126 4.5 4 32 30 122 126 120 102
60 120 90 35 35 1.8 1.8 126 130 3.3 3.5 45 46 562 247 124 120
61 125 120 25 26 0.8 0.9 142 140 4.2 4 45 46 142 152 120 145
62 108 120 31 32 0.9 0.9 144 130 2.8 3.6 21 26 100 100 156 200
63 100 120 20 26 0.8 0.8 144 126 4.5 4 32 30 122 126 120 102
64 125 79 45 46 1 1 147 139 4.2 4.2 99 101 987 356 298 200
65 96 102 45 2 1.2 1.2 140 135 3.3 3 89 95 421 254 156 120
66 152 102 30 30 1.2 1 126 1235 4 3.3 25 25 456 254 145 112
67 120 96 50 38 2 1 125 125 3 3.6 45 24 298 265 123 100
68 110 101 30 32 1.6 1.2 140 125 3 3 56 53 421 254 114 124
69 145 151 56 46 1.5 1.4 145 146 3.2 3.6 118 115 4260 1520 1280 456
70 156 120 25 26 2 1.2 135 130 4.2 4 45 56 3254 1263 875 458
71 80 86 50 42 0.9 0.9 144 145 3.7 3.7 640 256 125 144 120 110
72 86 90 25 24 1 1 135 132 4 3.3 56 53 452 251 111 120
DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3 DAY 1 DAY 3
NO
POTASSIUMSUGAR UREA SODIUM
RFT
LDHCREATININE
CARDIAC MARKERS
SGOT CPK 
73 145 142 30 32 0.8 1 126 130 4.2 4 45 52 456 125 124 103
74 120 136 26 28 0.9 0.9 147 140 3.8 3.6 44 46 120 114 126 125
75 100 120 20 26 0.8 0.8 144 126 4.5 4 32 30 122 126 120 102
76 256 120 25 26 2 1.2 145 136 4.2 4 45 56 4256 1263 789 458
77 145 142 30 32 0.8 1 126 130 4.2 4 45 52 456 125 124 103
78 152 102 30 30 1.2 1 126 123 4 3.3 25 25 456 254 145 112
79 102 94 154 40 1.4 1.4 134 125 4.1 3.2 145 156 250 190 708 250
80 104 93 32 25 0.8 0.8 145 136 3.7 3.5 36 36 2188 861 733 440
81 178 96 19 16 0.8 0.8 140 136 3.2 3.3 21 26 184 86 123 120
82 136 110 38 36 2 1.8 145 136 3.2 3.3 102 49 186 109 145 142
83 110 120 31 32 0.9 0.9 144 130 2.8 3.6 21 100 102 100 156 200
84 260 126 65 43 2.1 1.6 126 135 4.4 4 178 170 425 156 245 196
85 136 124 40 38 1.2 1 124 120 3.3 3 145 42 1265 253 135 123
86 98 102 38 34 2 1.8 145 136 3.2 3.3 148 140 291 142 135 142
87 145 105 58 46 1.5 1.4 146 125 3.2 3.6 118 115 4260 1520 1280 456
88 130 124 36 35 1 1 135 123 3.4 4 89 102 2568 241 458 365
89 106 90 25 28 0.8 1 125 132 3.5 3.3 56 45 241 251 111 156
90 140 110 42 30 0.6 0.8 125 130 4.2 3.2 25 26 1456 356 452 200
91 126 92 30 30 1.2 0.8 135 130 3.2 3 45 40 458 321 478 248
92 145 140 36 36 1.2 1.3 135 130 4 3.8 42 46 186 183 140 146
93 124 102 35 30 1 1 125 136 3 3.2 45 45 478 251 421 124
94 95 96 29 35 1.2 0.8 125 130 3.3 4 75 40 256 200 145 112
25 96 86 50 42 0.9 0.9 144 145 3.7 3.7 140 100 125 144 120 110
96 156 112 45 50 1.2 2 145 135 3.3 4 240 200 486 500 568 500
97 124 156 43 40 2 2 125 120 3 4 241 200 586 500 245 256
98 130 102 45 52 1.3 2 145 140 3 4 256 200 587 596 478 458
99 156 140 38 36 2 1.8 145 136 3.2 3.3 148 140 86 126 145 142
100 160 200 45 56 1.2 2 125 136 4.4 4 56 52 256 200 354 300
VENTILATORY SUPPORT VASOPRESSORS HEMODIALYSIS OUTCOME
WNL WNL NORMAL 0 21 YES RECOVERD
BRADYCARDIA WNL NORMAL 35 RECOVERD
WNL WNL NORMAL 29 YES RECOVERD
WNL WNL NORMAL 16 YES RECOVERD
WNL WNL NORMAL 23 NO RECOVERD
BRADYCARDIA WNL NORMAL 8 RECOVERD
T INVERSION V1‐V3 WNL NORMAL 16 8 8 NO RECOVERD
T INVERSION V1‐V3 WNL NORMAL 26 16 10 NO RECOVERD
BRADYCARDIA WNL NORMAL 16 16 NO RECOVERD
BRADYCARDIA WNL NORMAL 21 21 YES RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
WNL WNL NORMAL 21 8 13 YES YES RECOVERD
WNL WNL NORMAL 23 2 21 NO RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 19 12 5 NO RECOVERD
T INVERSION V1‐V3 WNL NORMAL 21 21 NO RECOVERD
POOR PROGRESSION 
OF R WAVES 
HYPOKINESIA LOWER 
2/3 OF IVS 
AND LV APEX
11 11 RECOVERD
BRADYCARDIA NORMAL 21 YES YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 21 21 RECOVERD
T INVERSION V1‐V3 WNL NORMAL 16 16 RECOVERD
RBBB RBBB NORMAL 21 21 YES YES RECOVERD
WNL WNL NORMAL 18 18 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
BRADYCARDIA WNL NORMAL 8 8 RECOVERD
ADS TALL R WAVES RT PR WNL GR 1 DD 20 12 8 NO RECOVERD
T INVERSION V1‐V3 WNL NORMAL 8 8 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
T INVERSION V1‐V6 WNL HYPOKINESIA  LV APEX 13 13 YES YES RECOVERD
BRADYCARDIA WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 18 18 NO RECOVERD
T INVERSION V1‐V3 WNL NORMAL 21 21 NO RECOVERD
DAY OF DISDAY 1 GH
ELECTROCARDIOGRAM TREATMENT GIVEN ASV
OUTSIDEECHO CARDIOGRAPHY TOTAL
VENTILATORY SUPPORT VASOPRESSORS HEMODIALYSIS OUTCOMEDAY OF DISDAY 1 GH
ELECTROCARDIOGRAM TREATMENT GIVEN ASV
OUTSIDEECHO CARDIOGRAPHY TOTAL
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 13 13 RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
T INVVERSION V1‐V4 WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 8 8 NO RECOVERD
WNL WNL NORMAL 16 8 8 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 YES YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL 16 16 YES YES DEATH
WNL WNL NORMAL 8 8 RECOVERD
T INVERSION V1‐V3 WNL NORMAL 16 16 NO YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
BRADYCARDIA WNL NORMAL 16 8 8 YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
T INVERSION V1‐V3 WNL NORMAL 16 16 NO RECOVERD
PR PROLONGATION WNL NORMAL 16 16 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 8 8 YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 8 8 YES RECOVERD
WNL WNL NORMAL 15 8 5 RECOVERD
WNL WNL NORMAL 8 8 NO RECOVERD
WNL WNL NORMAL 21 21 NO RECOVERD
WNL WNL NORMAL 8 0 8 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
BRADYCARDIA WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 8 8 NO RECOVERD
VENTILATORY SUPPORT VASOPRESSORS HEMODIALYSIS OUTCOMEDAY OF DISDAY 1 GH
ELECTROCARDIOGRAM TREATMENT GIVEN ASV
OUTSIDEECHO CARDIOGRAPHY TOTAL
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 8 RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 8 8 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
POOR PROGRESSION 
OF R 
WAVES RT PREC LEADS
WNL NORMAL 21 21 NO RECOVERD
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL NORMAL 8 8 NO RECOVERD
WNL WNL NORMAL 8 0 8 RECOVERD
WNL WNL NORMAL 16 0 16 YES RECOVERD
WNL WNL NORMAL 16 16 RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
WNL WNL NORMAL 21 21 RECOVERD
WNL WNL NORMAL 8 8 NO RECOVERD
WNL WNL NORMAL 16 8 8 NO RECOVERD
BRADYCARDIA WNL NORMAL 16 16 YES RECOVERD
POOR PROGRESSION
OF R WAVES  WNL NORMAL 13 5 8 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL NORMAL 16 16 NO RECOVERD
WNL WNL NORMAL 13 8 5 NO RECOVERD
WNL WNL NORMAL 8 8 RECOVERD
WNL WNL 16 16 YES YES DEATH
WNL WNL 16 8 8 YES YES DEATH
BRADYCARDIA WNL 16 16 YES YES DEATH
WNL WNL NORMAL 16 16 YES RECOVERD
WNL WNL 16 16 YES YES DEATH
 
